시장보고서
상품코드
1435375

세계의 에리스로포이에틴(EPO) 시장 보고서(2024년)

Erythropoietin (EPO) Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

에리스로포이에틴(EPO) 시장 규모는 향후 수년간 급속히 성장할 것으로 예상되고 있습니다. 2028년에는 12.6%의 연간 복합 성장률(CAGR)로 309억 2,000만 달러로 성장할 것으로 예상됩니다. 시장 경쟁, 바이오시밀러의 영향, 질병 확산 예측, 의료 정책 변화, 신흥 시장, 임상시험에 대한 관심 증가로 인해 성장이 가속화될 것으로 예상됩니다. 주요 동향으로는 공급망 관리의 발전, 세계 확장, 환자 교육, 상환 정책의 진화, 업계 통합 등이 있습니다.

만성 신장 질환의 유병률 증가로 인해 시장에서 에리스로포이에틴에 대한 수요가 증가할 것으로 예상됩니다. 만성 신장 질환 증가로 인해 적혈구 생성을 자극하여 면역력 향상을 돕는 에리스로포이에틴의 투여가 필요하게 되었습니다. 2021년 3월 질병통제예방센터(CDC) 보고서에 따르면 미국 성인의 약 15%(3,700만 명에 해당)가 만성콩팥병(CKD)을 앓고 있는 것으로 추산됩니다. 유병률은 65세 이상(38%)에서 가장 높고, 45-64세(13%), 18-44세(7%)가 그 뒤를 잇습니다. 만성 신장 질환으로 인한 빈혈 상태는 에리스로포이에틴에 대한 수요 증가에 기여하여 시장 성장을 가속할 것으로 보입니다.

에리스로포이에틴 시장의 성장은 에리스로포이에틴 의약품의 제조 및 판매를 관리하는 엄격한 규제에 의해 저해될 수 있습니다. 유럽공동체(EC)에서는 첨단 의약품, 특히 재조합 DNA 기술과 같은 생명공학 공정을 사용하여 제조된 의약품은 EC가 발행한 규정(EC) No.726/04에 명시된 판매 승인(MA) 규정을 준수해야 합니다. 에리스로포이에틴을 포함한 바이오시밀러의 규제 상황은 복잡하며, 주로 유럽의약품청(EMEA)이 제정한 가이드라인에 의해 관리되고 있습니다. 또한 재조합 인간 에리스로포이에틴(rHuEPO)은 EMEA가 정의한 품질, 임상 및 비임상 측면을 다루는 규정 외에도 해당 제품군 내의 특정 가이드라인을 준수해야 합니다.

목차

제1장 주요 요약

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 촉진요인과 억제요인
    • 시장 촉진요인
    • 시장 억제요인
  • 세계 시장 규모 실적과 성장, 2018-2023년
  • 세계 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 에리스로포이에틴(EPO) 시장, 제품별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 에포에틴 알파
  • 에포에틴 베타
  • 다베포에틴 알파
  • 기타 제품
  • 세계의 에리스로포이에틴(EPO) 시장, 약제 클래스별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 바이오로직스
  • 바이오시밀러
  • 세계의 에리스로포이에틴(EPO) 시장, 용도별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 혈액학
  • 신장병
  • 신경 내과
  • 기타 용도

제7장 지역 및 국가 분석

  • 세계의 에리스로포이에틴(EPO) 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 에리스로포이에틴(EPO) 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 에리스로포이에틴(EPO) 시장의 경쟁 구도
  • 에리스로포이에틴(EPO) 시장 기업 개요
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • F Hoffmann-La Roche Ltd.
    • Roche Holding AG
    • Novartis International AG

제31장 기타 대기업 및 혁신적 기업

  • LG Life Sciences Ltd.
  • LG Chem Ltd.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Chugai Pharmaceutical Co. Ltd.
  • Meiji Seika Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co. Ltd.
  • Dr Reddy's Laboratories Ltd.
  • 3SBio Inc.
  • Celltrion Inc.
  • Watson Pharmaceuticals Inc.
  • Biocon Limited
  • Emcure Pharmaceuticals Ltd.

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 합병과 인수

제35장 전망과 가능성 분석

제36장 부록

KSA 24.03.25

Erythropoietin (EPO) is a glycoprotein hormone naturally produced by the peritubular cells of the kidney, stimulating the production of red blood cells. It is utilized in the treatment of anemia, a condition characterized by a shortage of red blood cells. Symptoms of anemia, such as weakness, fatigue, and shortness of breath, arise due to the crucial role of red blood cells in delivering oxygen to tissues and organs.

The primary types of erythropoietin products include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Epoetin alfa is a recombinant DNA-derived human erythropoietin that is synthesized in cell culture. Erythropoietin falls into different drug classes, including biologics and biosimilars, and finds applications in various medical fields such as cancer, hematology, renal diseases, neurology, and others.

The erythropoietin (EPO) market research report is one of a series of new reports from The Business Research Company that provides erythropoietin (EPO) market statistics, including erythropoietin (EPO) industry global market size, regional shares, competitors with an erythropoietin (EPO) market share, detailed erythropoietin (EPO) market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (EPO) industry. This erythropoietin (EPO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The erythropoietin (epo) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $19.25 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historic period can be attributed to several factors, including increased patient education and awareness, consolidation within the pharmaceutical industry, policies related to healthcare reimbursement, expansion of the market coupled with demand growth, and the impact of patent expiration and entry of biosimilar products.

The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The forecasted growth is driven by market competition, biosimilar impact, disease prevalence projections, healthcare policy changes, emerging markets, and increased focus on clinical trials. Key trends include supply chain management advancements, global expansion, patient education, reimbursement policy evolution, and industry consolidation.

The increasing prevalence of chronic kidney diseases is expected to drive the demand for erythropoietin in the market. The rise in cases of chronic kidney disease necessitates the administration of erythropoietin, which stimulates the production of red blood cells, aiding in immune improvement. A report from the Centers for Disease Control and Prevention in March 2021 revealed that approximately 15% of adults in the United States, equating to 37 million people, were estimated to have chronic kidney disease (CKD). The prevalence is higher among individuals aged 65 or older (38%), followed by those aged 45-64 (13%), and those aged 18-44 (7%). The anemia conditions resulting from chronic kidney diseases contribute to an increased demand for erythropoietin, thereby fostering market growth.

The growth of the erythropoietin market may be hindered by stringent regulations governing the production and sales of erythropoietin drugs. In the European Community (EC), advanced medicinal products, especially those manufactured using biotechnological processes such as recombinant DNA technology, must comply with marketing authorization (MA) regulations outlined in Regulation (EC) No. 726/04 issued by the EC. The regulatory landscape for biosimilars, including erythropoietin, is intricate and primarily governed by guidelines established by the European Medicines Agency (EMEA). Additionally, recombinant human erythropoietin (rHuEPO) must adhere to specific guidelines within its product class, in addition to regulations covering quality, clinical, and non-clinical aspects, as defined by the EMEA.

The anticipated growth of the erythropoietin market is expected to be driven by the increasing incidence of hematologic cancer. Hematologic cancer constitutes a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including diseases such as leukemia, lymphoma, and myeloma. Erythropoietin (EPO) plays a crucial role in managing cancer-related anemia by stimulating the production of red blood cells, thereby alleviating anemia in cancer patients, particularly those undergoing chemotherapy. For instance, in 2023, the American Cancer Society estimates that leukemia is expected to affect 59,610 Americans and cause 23,710 deaths. Additionally, new cases of non-Hodgkin lymphoma are projected to impact 80,550 people in the United States, resulting in 20,180 deaths. Consequently, the increasing prevalence of hematologic cancers is driving the forward momentum of the erythropoietin market.

Major players in the erythropoietin market are introducing innovative products such as Yi Bao (Human Erythropoietin for Injection) to drive business growth, enhance productivity, and explore new markets. Yi Bao is a recombinant human erythropoietin produced using CHO cells. Wanbang Biopharmaceuticals Co. Ltd., a China-based pharmaceutical company, obtained approval from the National Medical Products Administration (NMPA) in September 2021 for Yi Bao's use in treating anemia caused by chemotherapy in patients with non-myeloid malignancies. Yi Bao closely resembles the imported innovator drug, exhibiting precise efficacy and fewer side effects.

Major players in the erythropoietin market are innovating with products such as Varenzin-CA1 to solidify their market position. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA designed to manage nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Elanco, a US-based pharmaceutical company, secured FDA approval for Varenzin-CA1 in May 2023. This breakthrough innovation for cats boasts a unique mode of action that triggers the genetic transcription of erythropoietin (EPO), leading to increased EPO and red blood cell production in a cat's body. Varenzin-CA1 sets a new standard of care for cats experiencing nonregenerative anemia due to CKD, offering convenience for at-home use.

Major companies operating in the erythropoietin (epo) market report are BASF SE, Hoffmann-La Roche AG, Merck Sharp & Dohme LLC, Sanofi SA, Thermo Fisher Scientific Inc., Associated British Foods PLC, DuPont de Nemours Inc., Kerry Group PLC, Firmenich SA, Koninklijke DSM NV, Dyadic International Inc., Novozymes A/S, Endo International PLC, Chr Hansen Holding A/S, Advanced Enzyme Technologies Ltd., Catalyst Pharmaceuticals Inc., Codexis Inc., AB Enzymes GmbH, Brain Biotech AG, Biocatalysts Ltd., Xike Biotechnology Co. Ltd., Amano Enzyme Inc., Enzyme Development Corporation, Lumis Biotech Pvt. Ltd., Teknisk-Kemiske Laboratorium ApS, Creative Enzymes Co. Ltd., BioResource International Inc., Enzyme Bioscience Pvt. Ltd., Sunson Industry Group Co. Ltd.

North America was the largest region in the erythropoietin (EPO) market in 2023. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Erythropoietin (EPO) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on erythropoietin (epo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for erythropoietin (epo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The erythropoietin (epo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Epoetin-alfa; Epoetin-beta; Darbepoetin-alfa; Other Products
  • 2) By Drug Class: Biologist; Biosimilar
  • 3) By Application: Cancer; Hematology; Renal diseases; Neurology; Other Applications
  • Companies Mentioned: BASF SE; Hoffmann-La Roche AG; Merck Sharp & Dohme LLC; Sanofi SA; Thermo Fisher Scientific Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Erythropoietin (EPO) Market Characteristics

3. Erythropoietin (EPO) Market Trends And Strategies

4. Erythropoietin (EPO) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Erythropoietin (EPO) Market Size and Growth

  • 5.1. Global Erythropoietin (EPO) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Erythropoietin (EPO) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Erythropoietin (EPO) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Erythropoietin (EPO) Market Segmentation

  • 6.1. Global Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Other Products
  • 6.2. Global Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biologis
  • Biosimilar
  • 6.3. Global Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cancer
  • Hematology
  • Renal diseases
  • Neurology
  • Other Applications

7. Erythropoietin (EPO) Market Regional And Country Analysis

  • 7.1. Global Erythropoietin (EPO) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Erythropoietin (EPO) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Erythropoietin (EPO) Market

  • 8.1. Asia-Pacific Erythropoietin (EPO) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Erythropoietin (EPO) Market

  • 9.1. China Erythropoietin (EPO) Market Overview
  • 9.2. China Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Erythropoietin (EPO) Market

  • 10.1. India Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Erythropoietin (EPO) Market

  • 11.1. Japan Erythropoietin (EPO) Market Overview
  • 11.2. Japan Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Erythropoietin (EPO) Market

  • 12.1. Australia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Erythropoietin (EPO) Market

  • 13.1. Indonesia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Erythropoietin (EPO) Market

  • 14.1. South Korea Erythropoietin (EPO) Market Overview
  • 14.2. South Korea Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Erythropoietin (EPO) Market

  • 15.1. Western Europe Erythropoietin (EPO) Market Overview
  • 15.2. Western Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Erythropoietin (EPO) Market

  • 16.1. UK Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Erythropoietin (EPO) Market

  • 17.1. Germany Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Erythropoietin (EPO) Market

  • 18.1. France Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Erythropoietin (EPO) Market

  • 19.1. Italy Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Erythropoietin (EPO) Market

  • 20.1. Spain Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Erythropoietin (EPO) Market

  • 21.1. Eastern Europe Erythropoietin (EPO) Market Overview
  • 21.2. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Erythropoietin (EPO) Market

  • 22.1. Russia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Erythropoietin (EPO) Market

  • 23.1. North America Erythropoietin (EPO) Market Overview
  • 23.2. North America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Erythropoietin (EPO) Market

  • 24.1. USA Erythropoietin (EPO) Market Overview
  • 24.2. USA Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Erythropoietin (EPO) Market

  • 25.1. Canada Erythropoietin (EPO) Market Overview
  • 25.2. Canada Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Erythropoietin (EPO) Market

  • 26.1. South America Erythropoietin (EPO) Market Overview
  • 26.2. South America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Erythropoietin (EPO) Market

  • 27.1. Brazil Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Erythropoietin (EPO) Market

  • 28.1. Middle East Erythropoietin (EPO) Market Overview
  • 28.2. Middle East Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Erythropoietin (EPO) Market

  • 29.1. Africa Erythropoietin (EPO) Market Overview
  • 29.2. Africa Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Erythropoietin (EPO) Market Competitive Landscape And Company Profiles

  • 30.1. Erythropoietin (EPO) Market Competitive Landscape
  • 30.2. Erythropoietin (EPO) Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F Hoffmann-La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Roche Holding AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis International AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Erythropoietin (EPO) Market Other Major And Innovative Companies

  • 31.1. LG Life Sciences Ltd.
  • 31.2. LG Chem Ltd.
  • 31.3. Amgen Inc.
  • 31.4. Teva Pharmaceutical Industries Ltd.
  • 31.5. Sandoz International GmbH
  • 31.6. Chugai Pharmaceutical Co. Ltd.
  • 31.7. Meiji Seika Pharma Co. Ltd.
  • 31.8. Sun Pharmaceutical Industries Ltd.
  • 31.9. Kyowa Kirin Co. Ltd.
  • 31.10. Dr Reddy's Laboratories Ltd.
  • 31.11. 3SBio Inc.
  • 31.12. Celltrion Inc.
  • 31.13. Watson Pharmaceuticals Inc.
  • 31.14. Biocon Limited
  • 31.15. Emcure Pharmaceuticals Ltd.

32. Global Erythropoietin (EPO) Market Competitive Benchmarking

33. Global Erythropoietin (EPO) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Erythropoietin (EPO) Market

35. Erythropoietin (EPO) Market Future Outlook and Potential Analysis

  • 35.1 Erythropoietin (EPO) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Erythropoietin (EPO) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Erythropoietin (EPO) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제